糖尿病合并急性脑梗死使用前列地尔联合阿替普酶治疗的疗效

Effect observation of alprostadil combined with alteplase in diabetes mellitus patients with acute cerebral infarction

目的探究糖尿病合并急性脑梗死时使用前列地尔联合阿替普酶治疗的疗效。方法对某院2017年2月~2018年2月收治的160例糖尿病合并急性脑梗死患者展开对照研究,将其分为观察组(前列地尔联合阿替普酶治疗)与对照组(阿替普酶治疗)各80例,分组方法为随机排列表法,探讨实施不同治疗方案对治疗效果的影响。结果观察组治疗后NIHSS评分少于对照组(P<0.05),观察组治疗后在D-二聚体、活化部分凝血活酶时间(APTT)以及血浆凝血酶原时间(PT)上显著比对照组高(P<0.05),在血浆纤维蛋白原(FIB)上显著比对照组低(P<0.05)。结论将前列地尔联合阿替普酶应用于糖尿病合并急性脑梗死患者时,可显著提升疗效,改善凝血与纤溶指标,减轻脑损伤。

Objective To study the efficacy of alprostadil combined with alteplase in diabetes mellitus patients with acute cerebral infarction.Methods 80 diabetes mellitus patients with acute cerebral infarction(February 2017~February 2018)were selected.According to random tabulation method,patients were assigned to observation group(n=40)and control group(n=40).The observation group was treated with alprostadil and alteplase;the control group was treated with alteplase.The curative effect was probed.Results After treatment,NIHSS(National Institute of Health stroke scale)scores in the observation group were significantly lower than that of the control group(P<0.05);the values of D-dimer contents,APTT(Activated partial thromboplastin time)and PT(Prothrombin time)in the observation group were significantly higher than that in the those of the control group(P<0.05);FIB(fibrinogen)contents in the observation group were significantly lower than control group(P<0.05).Conclusion The combination of alprostadil and alteplase can remarkably increase the clinical efficacy,improve the coagulation and fibrinolysis indicators and relieve the cerebral injury.